Clinical Trials Browser

Hodgkin Disease × Nivolumab × 90 days × Clear all

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03681561 2026-03-09

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1/2 Recruiting

54 enrolled

Lymphoid

Hodgkin Disease

NCT05255601 2026-02-25

RELATIVITY-069

Phase 1/2 Completed

5 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT03033914 2026-02-17

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Phase 1/2 Active not recruiting

82 enrolled

Lymphoid

Hodgkin Disease

Clinical Trials

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

RELATIVITY-069

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)